Pars Planitis Treatment Market to Reach $989.53 Billion by 2030 at 7.6% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Pars Planitis Treatment Market Expected To Scale Between 2026 And 2030?

The pars planitis treatment market size has experienced strong growth in recent years. It is projected to expand from $683.54 billion in 2025 to $737.86 billion in 2026, with a compound annual growth rate (CAGR) of 7.9%. Historically, this expansion can be ascribed to an improved understanding of uveitis pathophysiology, the availability of corticosteroid-based therapies, the proliferation of ophthalmology specialty clinics, increasing utilization of diagnostic imaging, and heightened clinical awareness of pars planitis.

The pars planitis treatment market is anticipated to experience robust expansion over the coming years. Projections indicate it will reach $989.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This projected growth is driven by several factors, including the increasing embrace of customized ophthalmic therapies, a heightened need for sustained inflammation management, the expansion of biologic drug development, an intensifying focus on methods to preserve vision, and greater financial commitments to cutting-edge ophthalmic diagnostic tools. Key trends anticipated during this period encompass the growing application of immunomodulatory interventions, the increasing uptake of biologic substances, a rising inclination towards specific anti-inflammatory approaches, the development of sophisticated ocular surgical methods, and an intensified emphasis on prompt diagnosis and continuous disease observation.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp

Which Primary Drivers Are Impacting The Pars Planitis Treatment Market Growth?

The rising occurrence of pars planitis is anticipated to boost the expansion of the pars planitis treatment market in the future. Pars planitis is defined as an idiopathic type of intermediate uveitis, predominantly leading to inflammation in the vitreous and the peripheral retina, commonly impacting individuals between 15 and 40 years old. This surge in pars planitis cases stems from enhanced awareness and better diagnostic abilities, facilitated by advanced imaging tools that allow for earlier and more precise detection. Treatments for pars planitis aid in its management by lessening ocular inflammation, thus proving crucial for vision preservation and complication prevention. These treatments improve patient care through targeted therapies, including corticosteroids and immunosuppressants, which contribute to better long-term eye health and an improved quality of life. For example, a case report from February 2025 by the US-based medical journal, Mega Journal of Case Reports, indicated that intermediate uveitis has an incidence of 1.4 to 2 cases per 100,000 people, with pars planitis, its idiopathic variant, making up 70% of these cases. Consequently, the rising prevalence of pars planitis is fueling the expansion of the pars planitis treatment market.

What Segment Categories Shape The Pars Planitis Treatment Market Segment Landscape?

The pars planitis treatment market covered in this report is segmented –

1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments

2) By Diagnosis: Blood Tests, Fundus Examination And Optical Coherence Tomography, Magnetic Resonance Imaging (MRI), Other Diagnosis

3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids

2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery

4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy

5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents

6) By Other Treatments: Antibiotics, Antivirals, Laser therapy

Which Trends Are Shaping Growth In The Pars Planitis Treatment Market?

Leading companies in the pars planitis treatment market are focused on developing innovative solutions, such as bispecific antibodies, to enhance immune modulation, decrease ocular inflammation, and minimize systemic adverse effects. Bispecific antibodies are engineered proteins designed to simultaneously bind to two distinct antigens or targets, offering more precise and effective treatment with fewer side effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion (RVO), supplementing its existing indications for age-related macular degeneration and diabetic macular edema. Vabysmo stands as the first bispecific antibody for ophthalmic use that targets both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), concurrently addressing inflammation and vascular leakage. This innovative mechanism is currently being explored for its potential application in intermediate uveitis, including pars planitis, where chronic inflammation in the retinal periphery necessitates durable and targeted intervention.

Who Are The Companies Operating Across The Pars Planitis Treatment Market Value Chain?

Major companies operating in the pars planitis treatment market are Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Quantum Cryogenics Ltd, Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Roche Holding AG, Pfizer Inc, Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, UCB SA, Bausch Health Companies Inc

Get The Full Pars Planitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report

Where Is The Pars Planitis Treatment Market Most Concentrated Geographically?

North America was the largest region in the pars planitis treatment market in 2025. The regions covered in the pars planitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pars Planitis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report

Browse Through More Reports Similar to the Global Pars Planitis Treatment Market 2026, By The Business Research Company

Hemoglobinopathies Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report

Hemoglobin Testing Market Report

https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report

Acquired Hemophilia Treatment Market Report

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795